These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36214792)

  • 1. Is HLA type a possible cancer risk modifier in Lynch syndrome?
    Ahadova A; Witt J; Haupt S; Gallon R; Hüneburg R; Nattermann J; Ten Broeke S; Bohaumilitzky L; Hernandez-Sanchez A; Santibanez-Koref M; Jackson MS; Ahtiainen M; Pylvänäinen K; Andini K; Grolmusz VK; Möslein G; Dominguez-Valentin M; Møller P; Fürst D; Sijmons R; Borthwick GM; Burn J; Mecklin JP; Heuveline V; von Knebel Doeberitz M; Seppälä T; Kloor M
    Int J Cancer; 2023 May; 152(10):2024-2031. PubMed ID: 36214792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.
    Sei S; Ahadova A; Keskin DB; Bohaumilitzky L; Gebert J; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Front Oncol; 2023; 13():1147590. PubMed ID: 37035178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations.
    Helderman NC; Bajwa-Ten Broeke SW; Morreau H; Suerink M; Terlouw D; van der Werf-' T Lam AS; van Wezel T; Nielsen M
    Crit Rev Oncol Hematol; 2021 Jul; 163():103338. PubMed ID: 34044097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
    Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    Bucksch K; Zachariae S; Aretz S; Büttner R; Holinski-Feder E; Holzapfel S; Hüneburg R; Kloor M; von Knebel Doeberitz M; Morak M; Möslein G; Nattermann J; Perne C; Rahner N; Schmiegel W; Schulmann K; Steinke-Lange V; Strassburg CP; Vangala DB; Weitz J; Loeffler M; Engel C;
    BMC Cancer; 2020 May; 20(1):460. PubMed ID: 32448342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
    Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
    Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
    Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
    Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
    Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
    Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients.
    Brand RE; Dudley B; Karloski E; Das R; Fuhrer K; Pai RK; Pai RK
    Fam Cancer; 2020 Apr; 19(2):169-175. PubMed ID: 31997046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.
    Hemminger JA; Pearlman R; Haraldsdottir S; Knight D; Jonasson JG; Pritchard CC; Hampel H; Frankel WL
    Hum Pathol; 2018 Aug; 78():125-130. PubMed ID: 29723603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mismatch repair testing in evaluation of Lynch syndrome: The gap between preferred and current practices.
    Williams D; Vilar E; Shakrukh Hashmi S; Choates M; Noblin S; Mork M
    J Genet Couns; 2020 Oct; 29(5):728-736. PubMed ID: 31896172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a vaccine to prevent cancer in Lynch syndrome patients.
    von Knebel Doeberitz M; Kloor M
    Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
    Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
    Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.
    Maletzki C; Huehns M; Bauer I; Ripperger T; Mork MM; Vilar E; Klöcking S; Zettl H; Prall F; Linnebacher M
    Mol Carcinog; 2017 Jul; 56(7):1753-1764. PubMed ID: 28218421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.